Clinical trial · Observational
Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
Biomarkers of Survival in HNSCC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Study closed prematurely upon PI's departure
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response to treatment in patients with newly diagnosed stage III or stage IV head and neck cancer treated with carboplatin, paclitaxel, and radiation therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Cancer | Malignant Head and Neck Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DNA Microarray analysis | Genetic | — | UNRESOLVED |
| DNA microarray and MALDI-TOF mass spectrometry | Genetic | — | UNRESOLVED |
| MALDI-TOF mass spectrometry | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Head and neck squamous cell carcinoma patients (HNSCC)
- interventionNames
- Genetic: DNA Microarray analysis
- Genetic: MALDI-TOF mass spectrometry
- Genetic: DNA microarray and MALDI-TOF mass spectrometry
Primary outcomes (1)
- measure
- Survival
- timeFrame
- at expiration of last patient enrolled
Secondary outcomes (1)
- measure
- Treatment response
- timeFrame
- upon patient tissue collection
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Newly diagnosed head and neck squamous cell carcinoma * Stage III-IV disease * Scheduled for pan-endoscopy * Tumor tissue available from patients treated with carboplatin, paclitaxel, and radiotherapy on protocol VU-VICC-HN-0356 PATIENT CHARACTERISTICS: * Able to speak English PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available